GlaxoSmithKline has begun a Phase III study cardiovascular outcomes study of its investigational compound losmapimod in patients with acute coronary syndrome. The trial will assess whether losmapimod can reduce the risk of a subsequent cardiac event when administered orally twice … Continue reading
June 9, 2014
by PharmaReviews
1 Comment